Imsidolimab

Name: Imsidolimab in Generalized pustular psoriasis: Pharmacodynamics
Published: 2026-09-14T15:39:06-04:00

Generalized pustular psoriasis

Manufacturer: Vanda Pharmaceuticals
Regulatory submission: BLA submitted December 2025
Launch: Anticipated in the first half of 2027
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information Pharmacology

Pharmacodynamics

1 evidence topic · 1 source

Phase 1 pharmacodynamics: duration of suppression and ex vivo assay

“completely suppress IL-36 cytokine function for 85 days” (opens the source at this quote in a new tab)
“IL-36 cytokine-mediated release of IL-8 using an ex vivo pharmacodynamic assay.” (opens the source at this quote in a new tab)